Personnel

Proteomics company names Dr. Wenpei Su as director of genomics applications

Published in Gene Therapy Weekly, August 5th, 2004

CeMines, Inc., a privately held company founded in 2000 that uses genomics and proteomics information as the fundamental building blocks for gene regulation, has appointed Wenpei Su, PhD, as the company's first director of genomics applications, effective immediately.

CeMines' research and clinical efforts are focusing on molecular mechanisms of the fundamental processes of gene expression-transcription and RNA processing (gene-splicing factors). The company is aggressively pursuing commercialization of a patent-pending platform technology known as CeMines Molecular FingerPrinting focused on development of early-stage diagnostics and targeted therapeutics for cancer and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2004-08-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry